GNTA Genenta Science S.p.A.

Nasdaq genenta.com


$ 4.99 $ 2.97 (91.95 %)    

Friday, 24-Oct-2025 19:58:49 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 6.2
$ 9.88
$ 4.56 x 190
$ 5.45 x 250
$ 5.68 - $ 10.00
$ 2.56 - $ 10.00
21,595,070
na
113.4M
$ 0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genenta-extends-collaboration-with-anemocyte-to-boost-off-the-shelf-genetic-therapy-production

Genenta Science shares jumped ~324% premarket to $13.69 after expanding its plasmid DNA collaboration with ANEMOCYTE.

Core News & Articles

INTC: 9% | Intel shares are trading higher after the company reported Q3 EPS and sales above expectations. COIN: 3% | Coinbase ...

 genenta-science-collaborates-with-anemocyte-for-manufacturing-critical-starting-materials-for-cutting-edge-cell-based-therapies

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collabor...

 genenta-science-secures-219m-funding-via-mandatory-convertible-bond-from-enea-tech-to-advance-temferon-in-metastatic-renal-cell-cancer

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 mill...

 hc-wainwright--co-reiterates-buy-on-genenta-science-maintains-25-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Genenta Science (NASDAQ:GNTA) with a Buy and maintains $25 price...

 hc-wainwright--co-reiterates-buy-on-genenta-science-maintains-25-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Genenta Science (NASDAQ:GNTA) with a Buy and maintains $25 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION